Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 70
Updated:2/17/2019
Start Date:September 24, 2018
End Date:November 25, 2019
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects

The primary purpose of this study is to evaluate the effect of hepatic impairment on the
systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with
hepatic impairment. The results of this study will support treatment and dosing decisions for
patients with varying degrees of hepatic impairment.


All subjects:

Inclusions Criteria:

- Subjects must weight at least 50 kg, with a BMI within the range of 18 to 38 kg/m2

- Must be willing to remain in the clinical research unit as required by the protocol

Exclusion Criteria:

- Use of other study drugs at the time of enrollment, or within 5 half-lives of
enrollment, or within 30 days, whichever is longer; or longer if required by local
regulations

- History of hypersensitivity to the study treatment or to drugs of similar chemical
classes

- Pregnant or nursing women

- Women of child-bearing potential

Healthy Volunteers:

Inclusion Criteria:

- In good health as determined by past medical history, physical examination, ECG,
laboratory tests, and urinalysis at Screening.

Exclusion Criteria:

- Liver disease or liver injury

- Chronic infection with Hepatitis B or Hepatitis C

- History or presence of impaired renal function

Hepatically Impaired Subjects:

Inclusion Criteria:

- Hepatic impairment as defined by the Child-Pugh classification for severity of liver
disease

Exclusion Criteria:

- Severe complications of liver disease within the preceding 3 months

- Emergency room visit or hospitalization due to liver disease within the preceding 3
months

- Subject has received liver transplant at any time in the past and is on
immunosuppressant therapy

- Acute Hepatitis B or Hepatitis C infection

Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
2
sites
Knoxville, Tennessee 37934
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials